Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
08:30am, Wednesday, 06'th Aug 2025
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches t
Fractyl Health Announces Proposed Public Offering
04:15pm, Tuesday, 05'th Aug 2025
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches t
Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or
Fractyl Health: Speculative Buy With Binary Risk
10:13am, Wednesday, 16'th Jul 2025
Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected in Q3 2025. Current valuation reflects financing and trial risks, but may und
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
07:00am, Wednesday, 18'th Jun 2025
Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl's leadership in metaboli
BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1 TM gene therapy for patients with inadequately controlled T2D and obesity
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adh
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development an
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
08:43pm, Tuesday, 13'th May 2025
Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Brian Luque - Head of Investor Relations and Corporate Development Harith Rajagopalan
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
04:05pm, Tuesday, 13'th May 2025
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root cau
